EEF1B2

Across TCGA pan-cancer cohorts, EEF1B2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EEF1B2 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher EEF1B2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EEF1B2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

GBM, HNSC, and PDAC are the cancer types where EEF1B2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.244	0.604	.002	26	view →
HNSC	DFS	Median	All	1.000	0.393	.018	7	view →
PDAC	DFS	Quartile	All	0.859	0.748	.024	4	view →
CCRCC	OS	Quartile	All	0.589	1.000	.017	3	view →
LSCC	OS	Quartile	All	0.801	0.927	.039	1	view →
LUAD	DFS	Quartile	All	0.995	0.856	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EEF1B2–GBM (DFS)

Open the GBM breakdown →